People: Ablynx NV (ABLX.BR)

ABLX.BR on Brussels Stock Exchange

9.22EUR
26 Mar 2015
Change (% chg)

-- (--)
Prev Close
€9.22
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
179,139
52-wk High
€11.48
52-wk Low
€7.40

Search Stocks

Summary

Name Age Since Current Position

Peter Fellner

70 2013 Chairman of the Board

Edwin Moses

59 2013 Chief Executive Officer, Member of the Executive Management, Director

Wim Ottevaere

57 2006 Chief Financial Officer, Member of the Executive Management

Kim Simonsen

39 Chief Operations Officer, Member of the Executive Management

Antonin de Fougerolles

2013 Chief Scientific Officer, Member of the Executive Management

Frank Landolt

Vice President of Intellectual Property and Legal, Member of the Executive Management

Guido Gielen

Vice President of Human Resources, Member of the Executive Management

Dominique Tersago

2013 Chief Medical Officer, Member of the Executive Management

Russell Greig

63 Independent Director

Bo Hansen

57 Independent Director

William Jenkins

66 Independent Director

Catherine Moukheibir

56 Independent Director

Remi Vermeiren

73 Independent Director

Biographies

Name Description

Peter Fellner

Dr. Peter J. Fellner, Ph.D., has served as Chairman of the Board of Directors of Ablynx NV since 2013. He is currently Chairman of the Board of Consort Medical and Optos. In addition, he serves as Chairman of the biotech companies Vernalis and Biotie Therapies, and is Vice Chairman of Astex Pharmaceuticals, which is being acquired by Otsuka Pharmaceuticals. He is currently a Director of the global biopharmaceutical company UCB, where he is Chairman of the Science Committee of the Board, and is a Member of the Novo A/S Advisory Group. He previously served as Chairman of Acambis from 2006 until its acquisition by Sanofi Aventis in 2008, and of Premier Research Group from 2007 to 2008, when it was acquired by a private-equity backed group. He also served as Chairman of Celltech Group from 2003 to July 2004, until its acquisition by UCB, having been Chief Executive Officer from 1990 onwards. Before joining Celltech, he was Chief Executive Officer of Roche UK from 1986 to 1990.

Edwin Moses

Dr. Edwin Moses, Ph.D., has served as Chief Executive Officer, Member of the Executive Management of Ablynx NV since June 6, 2006. He has also served as Member of the Board of Directors of the Company since 2004. He also served as Chairman of the Board of Directors of the Company between 2004 and 2006, and again between June 6, 2006 and 2013. After he completed his post-doctoral research in Germany, he started his career at Amersham International, Enzymatix and Raggio-Italgene. From 1993 until 2001, he worked at Oxford Asymmetry, first as Chief Executive Officer and later as Chairman until 2001. Apart from and in addition to his duties at the Company, he is Chairman of Lectus Therapeutics Ltd., Chairman of the Board of Capricorn Health-tech Fund (Belgium) and Member of the Board of Directors of the European Biopharmaceutical Enterprises. Furthermore, in the past five years, in addition to Ablynx NV, he has held Board memberships with the following companies: Clinphone Group plc, Fusion IP plc (formerly Biofusion plc), Phoqus Pharmaceuticals Ltd, Pharmaceutical Profiles Ltd, Proimmune Ltd, Paradigm Therapeutics Ltd, Avantium Technologies (the Netherlands), Ionix Pharmaceuticals Ltd, Evotec OAI AG, Bioimage A/S, Inpharmatica Ltd, Prolysis Ltd, ProPharma Ltd, Lectus Therapeutics Ltd and the European Biopharmaceutical Enterprises.

Wim Ottevaere

Mr. Wim Ottevaere has served as Chief Financial Officer and Member of the Executive Management of Ablynx NV since 2006. He holds a Masters degree in Business Economics from Universiteit Antwerpn, Belgium. From 1978 until 1989, he held various positions in finance and administration within the Dossche group. From 1990 until 1992, he served as Finance Director of Vanhout, a subsidiary of the Besix group, a construction enterprise in Belgium. From 1992 until July 2006, he was Chief Financial Officer of Innogenetics, a biotech company listed on Euronext. He joined the Company in August 2006.

Kim Simonsen

Mr. Kim Simonsen serves as Chief Operations Officer and Member of the Executive Management of Ablynx NV. He received a Doctorate of Medicine degree from the University of Copenhagen and had clinical training for five years before moving into the pharmaceutical industry. He has experience within the field of particularly Clinical Drug Development in the European Union, the United States, Japan and China in different therapeutic areas. He has worked with Sandoz, Novo Nordisk, Novartis, Medicon (a CRO) and as Vice President for Global Clinical Development at ALK-Abello before moving to the Company. He has been given lectures in Clinical Pharmacology and Drug Development in Denmark, within the Association of the Pharmaceutical Industry in Denmark and at Copenhagen and Aalborg University.

Antonin de Fougerolles

Dr. Antonin (Tony) de Fougerolles, Ph.D., has served as Chief Scientific Officer and Member of the Executive Management of Ablynx NV since October 2013. He has more than 15 years of biotech research and development experience and knowledge in building out pipelines and expanding platform technologies. Prior to joining the Company, he was Chief Scientific Officer at Moderna Therapeutics where he led the Science Department. Previously, he was Chief Scientific Officer at Tolerx Incand, and prior to that he served on the management team of Alnylam Pharmaceuticals as Vice President, Research, Immunology, Metabolic, and Viral Disease from 2003 to 2010. He also served as a Principal Scientist at Biogen, Inc. (now Biogen Idec Inc.) from 1998 to 2003, where he worked on several immunology/inflammation-based programs and led research teams working to develop antibody-based therapeutics. He earned his Doctorate in Philosophy degree in Immunology from Harvard University, and was an Arthritis and Rheumatism Council Research Fellow at the Laboratory of Molecular Biology in Cambridge, England.

Frank Landolt

Mr. Frank Landolt serves as Vice President of Intellectual Property and Legal and Member of the Executive Management of Ablynx NV. He is a Dutch and European patent Attorney and transactional Lawyer who joined the Company in 2004. He started his career in private practice in the Netherlands, where his clients included pharmaceutical companies, as well as some biotech companies and research institutions in the Netherlands. From 2000 to 2004, he was Director of Intellectual Property and Legal at Devgen, another Belgian biotech company. He holds a degree in Chemistry from Universiteit Leiden, a degree in Civil Law from Universiteit Leiden, and a degree in Business Law from Universiteit Antwerpen.

Guido Gielen

Mr. Guido Gielen serves as Vice President of Human Resources and Member of the Executive Management of Ablynx NV. He obtained a Masters degree in Sociology from Katholieke Universiteit Leuven. Prior to his position at the Company, he held several local and international human resources positions within Johnson & Johnson from 1990 to 2010. During this period, he worked with client groups in Operations, General Services, Sales and Marketing and Research and Development in Western Europe, Central and Eastern Europe, the United States and Asia.

Dominique Tersago

Ms. Dominique Tersago has served as Chief Medical Officer and Member of the Executive Management of Ablynx NV since July 2013. She joined the Company in January 2011 to head the Medical group. Prior to joining the Company, she was Director Regulatory Strategy, Europe with Bristol-Myers Squibb International in the therapeutic areas of oncology and virology. She received her Doctorate of Medicine degree from Universiteit Antwerpen, Belgium. She joined the pharmaceutical industry in 1994 with Janssen Research Foundation (Johnson & Johnson) and has held positions in clinical development and regulatory strategy.

Russell Greig

Dr. Russell G. Greig, Ph.D., serves as Independent Member of the Board of Directors of Ablynx NV. He has more than 30 years of experience in the pharmaceutical industry, with knowledge in research and development, business development and commercial operations. He spent the majority of his career at GlaxoSmithKline, where he held a number of positions including GSK’s President of Pharmaceuticals International from 2003 to 2008 and Senior Vice President Worldwide Business Development. From 2008 to 2010, he was also President of SR One, GSK’s Corporate Venture Group. He is currently Chairman of Syntaxin (the United Kingdom), AM Pharma (The Netherlands) and Isconova (Sweden) as well as Director of Tigenix (Belgium). He also acts as a Consultant to Genocea (the United States), BigDNA (Scotland), Edinburgh BioQuarter (Scotland), and Kurma Life Sciences (France). He served as acting Chief Executive Officer at Genocea and Isconova for an interim period. He is also Member of the Scottish Scientific Advisory Committee. He holds a Bachelor of Science degree from the University of Manchester and a Doctorate in Philosophy degree in Biochemistry from the University of Manchester.

Bo Hansen

Dr. Bo Jesper Hansen, M.D., Ph.D., serves as Independent Member of the Board of Directors of Ablynx NV. He currently serves as Executive Chairman of the Boards of Swedish Orphan Biovitrum and TopoTarget. He is also Non-Executive Director of a number of biotech and pharmaceutical companies including Orphazyme, Newron Pharmaceuticals, CMC AB, Hyperion Therapeutics and Genspera. He served as Chief Executive Officer and President and as Director to the Board of Swedish Orphan International until the acquisition of Biovitrum, forming Swedish Orphan Biovitrum. He also was Non-Executive Director of Gambro until its acquisition by Baxter, and Zymenex, until its acquisition by Chiesi. He founded Scandinavian Medical Research during which he served as Medical Advisor for Synthelabo, Pfizer, Pharmacia and Yamanouchi Pharmaceutical. He received a degree in Medicine from Koebenhavns Universitet and a Doctorate in Philosophy degree from Koebenhavns Universitet.

William Jenkins

Dr. William J. Jenkins, M.D., serves as Independent Member of the Board of Directors of Ablynx NV. He is Principal of William Jenkins Pharma Consulting and has been advising a range of pharmaceutical and biotech companies, and investment and venture capital firms in the healthcare sector since 1999. Formerly, he was Head of Worldwide Clinical and Regulatory Affairs for Novartis Pharma and held a similar position with Glaxo Group Research Limited. He is currently Senior Independent Director of Consort Medical, an ad hoc Member of the Board of Evotec and a Member of the Advisory Board of Chiesi Farmaceutici. In addition, he serves as Chairman of the Scientific Advisory Board of Evotec and is a Member of the Scientific Advisory Boards of BB Biotech Ventures II and III funds, and until recently Nicholas Piramal India. He received a Doctorate of Medicine degree from the University of Cambridge and a Master of Arts degree from the University of Cambridge.

Catherine Moukheibir

Ms. Catherine Moukheibir serves as Independent Member of the Board of Directors of Ablynx NV. She has been in C-level positions in several European biotech companies after an initial career in strategy consulting and investment banking in Boston and London. Her particular experience lies in aligning corporate and financial strategy appropriate to various stages of a biotech’s development, on the continuum from venture capital funding to public market or mergers and acquisitions. She is currently a Non-Executive Board Member of Creabilis and a Member of the three-person Executive Committee at Innate Pharma where she is responsible for financial and corporate strategy. She holds a Masters degree from Yale University and a Masters of Business Administration degree from Yale University.

Remi Vermeiren

Mr. Remi Vermeiren serves as Independent Member of the Board of Directors of Ablynx NV. He is Chairman of the Company's Audit Committee. Before he became Independent Member of the Board of Directors of the Company, he had a 43 year long career at Kredietbank NV, which in 1998 merged with Cera Bank and ABB Insurance into KBC Bank and Insurance Group. In the earlier years, he was mainly involved in Asset Management, Trading and Administration of Securities, Treasury and International and Investment banking. From 1989 on, he was Member of the Executive Committee responsible for the day-to-day management of the bank. From 1998 until 2003, he held the function of Chairman of the KBC Bank and Insurance Group and of KBC Bank. Currently, he is also Member of a number of quoted and non-quoted companies and of charitable organizations, including of Foundation RV set up and funded by himself. He is currently Member of the Board or supervisory bodies of the following companies: ACP II SCA (Liquidator) and Zinner NV . In the past five years, he has held positions as a Member of the Board or administrative, management or supervisory bodies of the following companies: Hobbyrama NV, Gondry SA, Hout Van Steenberge NV, Cometal NV, Stock Van Wiemeersch NV, Capital Markets Company NV, Ardatis NV, Afinia Plastics NV, Euronext Holding N.V., Euronext Amsterdam N.V., IFB SPA, Cumerio NV and Ravago NV, Devgen NV . He holds a degree in Commercial and Financial Sciences.
Search Stocks